Moniyot-131 Zur Therapie (Sodium Iodide (131i))

Sodium Iodide (I-131), the active ingredient in Moniyot-131 Zur Therapie, is a radiopharmaceutical presented as an oral preparation for systemic use. It is employed in the selective ablation of thyroid tissue for patients with residual thyroid tissue after surgery, hyperthyroidism, or differentiated thyroid carcinoma. GNH USA supplies Moniyot-131 Zur Therapie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Moniyot-131 Zur Therapie is a radioactive iodine agent used in thyroid‑related disease management. It targets thyroid tissue to achieve therapeutic ablation. - Ablation of residual thyroid tissue after thyroidectomy: eliminates remaining thyroid cells post‑surgery. - Treatment of hyperthyroidism (e.g., Graves' disease): reduces excess thyroid hormone production. - Management of differentiated thyroid carcinoma: destroys malignant thyroid cells and helps prevent disease recurrence.

Adverse reactions may occur following oral administration of I-131.

Common Side Effects: - Nausea or vomiting. - Dry mouth or altered taste sensation. - Transient sialadenitis (salivary gland inflammation). - Mild leukopenia or fatigue.

Serious or Rare Side Effects: - Severe sialadenitis requiring medical intervention. - Bone marrow suppression leading to pancytopenia. - Pulmonary fibrosis or interstitial lung disease. - Allergic reactions including rash or anaphylaxis. - Secondary malignancies due to radiation exposure.

Use of Moniyot-131 Zur Therapie requires careful patient assessment and safety measures. - Pregnancy: avoid unless benefits outweigh potential fetal risks. - Breastfeeding: contraindicated; discontinue nursing prior to therapy. - Thyroid function: confirm diagnosis and baseline labs before administration. - Renal function: evaluate and adjust if significant impairment exists. - Radiation safety: implement shielding and limit exposure to staff and family. - Store at ambient temperature: keep in original container, protect from moisture and light.

I-131 therapy can be affected by other medications that influence iodine metabolism or bone marrow function.

Major Interactions (Avoid): - Thyroid hormone replacement: may diminish therapeutic efficacy. - Antithyroid drugs (e.g., methimazole, propylthiouracil): interfere with iodine uptake. - Lithium: alters thyroid iodine handling and can reduce treatment response.

Moderate Interactions (Monitor Closely): - Potassium iodide: can block I-131 uptake if administered shortly before therapy. - Amiodarone: high iodine load may affect treatment outcomes. - Chemotherapeutic agents causing bone marrow suppression: increase risk of hematologic toxicity.